Key Takeaways
- Product leverage drove a disproportionate profit jump: Revenue grew ~20% in FY23, but profits rose fourfold because licensing the iFile product to central banks carries almost no incremental cost, unlike services revenue.
- The Collect order book just got materially stronger: Late-FY23 wins from the Bhutan and South African central banks, plus a pipeline of 4–5 active regulator proposals, set the segment up for a potential new growth trajectory.
- Create segment hit a Q4 air pocket from partner consolidation: A Big 4 U.K. partner took XBRL work in-house and a few European companies shifted filings into Q1, causing a year-on-year dip; the underlying customer concentration is actually improving as Create scales.
- Fundraising remains the unresolved catalyst: Management reiterated it needs to raise money “sooner than later” to fund marketing and attack the U.S. SEC market, but offered no update on timing or structure.
- What to watch next half-year: Whether the SARB contract scope and IRIS’s revenue share firm up, any Disclosure Management pricing signal from the 50–60-customer trial, and concrete progress on a fundraise.
The Product Profitability Engine
- Operating leverage is structural, not cyclical: While revenue moved up 21%, overall expenses grew only 18%, continuing a long-term pattern of ~18% topline CAGR against 11–12% expense growth. Employee costs rose ~17% as the company spent to retain talent in a tight market, though that pressure is now easing.
- The “magic of product revenue”: Licensing iFile to a central bank generates revenue with no corresponding increase in cost. This is why a 20% revenue lift produced a fourfold profit jump, a dynamic that does not exist in linear services businesses.
- Receivables spike was timing, not stress: Receivables rose to ~INR 24 cr from ~INR 15 cr because two substantial Collect invoices were raised in March from late-year wins. Management stated the money has since come in and receivable levels are back to normal.
Swaminathan: “So 20% of revenues and a fourfold jump in profitability, and for which we are grateful. ... when you license those products to them, when you book those revenues, so it's the magic of the product revenue, where there's no corresponding increase in cost.”
Collect: Central Bank Wins & Pipeline
- Two landmark wins closed late in FY23: The Royal Monetary Authority of Bhutan licensed iFile for a collection platform and analytics, with revenue billed in Q4. The South African Reserve Bank licensed iFile for a deposit insurance system, a win described as “very substantial.”
- SARB is a product-creation opportunity, not just a project: Once built, the deposit insurance system has applications across Africa and globally, a need management called “huge” in the context of recent U.S. bank failures. The scope of work is already starting to expand.
- SARB revenue visibility is still fuzzy: Contracting is not complete and the division of work with the local partner is still being negotiated. Management hopes to share IRIS’s precise proportion next quarter, with revenues spread over 3–4 years on a milestone basis.
- Pipeline has revived to pre-COVID levels: About 4–5 regulators are expressing interest, with 4–5 proposals pending and under evaluation by three countries. Management can “reasonably say there will be 3, 4, 5 countries going in the RFP direction.”
- Pricing flexibility is a deliberate posture: Post-COVID budget constraints in many countries mean IRIS is being flexible on pricing. Management is confident the strike rate will be no inferior to earlier periods.
- “iFile in a box” exists but is unsold: The company has developed a minimal-implementation version for rapid deployment into any country, but has not yet sold a single license.
Create: The Q4 Dip & Partner Risk
- Three forces drove the Q4 Create revenue decline: A major U.K. partner (one of the Big 4) consolidated vendors and took XBRL work in-house using its own India-based center. A shift in the CARBON segment saw several European companies move annual filings from Q4 to Q1. South Africa reduced the number of companies mandated to file, though IRIS increased its share of the smaller mandate.
- The U.K. partner loss was a strategic retreat by the partner: The partner initially used multiple vendors but consolidated over time because it did not see the HMRC/XBRL opportunity as large as initially expected, and it already had a team based out of India that it used to take the remaining work in-house.
- A U.S. energy partner also departed, but customers were retained: The partner was a start-up that wanted to build its own solution. When the partnership broke, IRIS transitioned or retained almost all customers bar one.
- Customer concentration is improving structurally: Because the Create segment (smaller ticket, larger number of customers) is now much bigger than Collect, overall customer concentration has come down significantly.
Swaminathan: “We are constantly living in paranoia what is the possibility of losing customers because of these things, it can happen. And Deepta has her ears closer to the ground than I do. But it's a question that keeps bothering me constantly.”
U.S. Market: Disclosure Management & Municipal Reporting
- Disclosure Management is in paid trial: About 50–60 paying customers are using the offering. Price discovery is still 6 months away; the company expects to have enough data points to develop a pricing algorithm over that period as usage grows.
- The SEC filing market is the big prize, but IRIS has not yet attacked it: Management cited insufficient funding and marketing muscle as the reason. The plan is to target the ~1,000 filers who switch vendors annually, typically toward the end of the calendar year after 10-K preparation.
- Municipal (ACFR) opportunity is state-by-state and mandate-dependent: IRIS has pilots completed with about 4 U.S. states, is working with XBRL US on promotion, and has had staff traveling extensively to U.S. conferences. Rollout will follow the Financial Data Transparency Act’s state-by-state mandate timeline.
- ESG and FERC Phase 2 are in seeding mode: Both opportunities require waiting for official mandate dates from regulators. Early marketing, engagement, and pilots are underway.
Automation, AI & the Pricing Question
- ChatGPT experimentation is internal and cautious: A team is experimenting with automation and LLM models. Management’s view is that 90% accuracy is not enough for regulatory filing, where 100% correctness is required.
- Automation is expected to accelerate adoption, not destroy demand: Management believes automation will make more regulators comfortable connecting structured data and expanding mandates across large and small companies, moving faster than the historical gradual approach.
- The pricing risk is acknowledged, not dismissed: Management is “confident that the impact it will have is not on losing a customer, but perhaps on price.”
- The core thesis is unchanged: The business remains about delivering solutions that create structured data for consumption by the regulator.
Swaminathan: “90% of the time, there is a 10% where it does not really work. And when it comes to filing, you can't be 90% accurate, you have to be 100% right.”
Fundraising & Capital Strategy
- The need is explicit and urgent: Management stated it “obviously needs to raise money” and must do it “sooner than later” to get on a much higher growth path, acknowledging the long-running discussion has become “almost like a bad joke.”
- No update on timing or structure: The rights issue option has not been abandoned but the Board must decide. Management declined to “stick my neck out and see what will happen finally.”
- Organic cash generation is a partial bridge: The fact that the company is throwing up cash makes fundraising slightly easier and allows some marketing and brand building to happen organically, but competitors have deep pockets and IRIS needs capital to attack the U.S. SEC market properly.
Swaminathan: “I know it's almost like a bad joke. The amount of time that you have spent in talking about raising money, but not doing it. But it's something that we need to do sooner than later if we want to get on to a much higher growth path.”
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Collect revenue trajectory | Execute on robust order book to enter a new growth trajectory | Not dated (conditional on execution) |
| SARB revenue share disclosure | Provide precise estimate of IRIS’s proportion once contracting is complete | Next quarter |
| Disclosure Management pricing | Develop a pricing algorithm from trial data | Next 6 months |
| Fundraise | Raise capital to fund marketing and higher growth | “Sooner than later” (no date) |
| Earnings call cadence | Next call in 6 months; management prefers half-yearly view | 6 months from now |
| IRP revenues | Expected to kick in and be very valuable | Next 12–36 months |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue growth | 21% YoY for FY23 |
| EBITDA growth | 38% YoY for FY23 |
| Profit growth | Fourfold increase YoY for FY23 |
| Revenue CAGR (since IPO) | ~18% |
| Expense CAGR (since IPO) | 11% to 12% |
| Employee cost growth | 17% YoY for FY23 |
| Collect segment revenue growth | 15% YoY for FY23 |
| Annual recurring revenue growth | 17% to 18% YoY for FY23 |
| Recurring revenue share | 75%, down from 78% in FY22 |
| India revenue share | 38%, down from 45% in FY22 |
| Receivables | ₹24 cr, up from ₹15 cr in FY22; normalized post-quarter |
| Create revenue Q4 YoY | Decreased (per an analyst's math) |
| Large-deal pipeline | 4 to 5 proposals pending, evaluated by 3 countries |
| Bhutan implementation size | $1 mn to $2 mn, execution over 12 to 18 months |
| SARB implementation duration | 3 to 4 years, revenues of similar order each year |
| Disclosure Management paying customers | 50 to 60 on Freemium model |
| Total customers served | ~6,200 |
| SEC filer vendor churn | ~1,000 companies switch vendors annually |
| DM provider market rank | Number 2, behind Workiva |